SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is drawing attention after a sharp breakout to a 52-week high, with traders focused on heavy call buying and positioning ahead of the Q3 report. Buyout and short-squeeze theories are circulating, but remain speculation; others point to BRIUMVIs sales growth as the underlying driver.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

Roots Hyundai Secure+ partnership is drawing attention after the product was identified as powered by Root, with traders focused on its potential to expand embedded, dealership-based insurance sales. Bulls see Hyundai and Kias vehicle sales as a significant distribution opportunity, while skeptics question how quickly the rollout can translate into policy growth amid recent concerns about declining policies in force.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is drawing attention ahead of its quarterly results, with traders focused on GMV and take rate as well as whether payments-heavy growth can offset margin pressure and rising credit costs. The discussion is split between hopes for a strong report and concerns about the recent pullback and earnings risk.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLakes BLA submission for sonelokimab in hidradenitis suppurativa has put FDA acceptance and the review timeline at the center of discussion. Traders are split between optimism about the drugs potential and a possible partnership or acquisition, and concerns about regulatory risk, competition, and the cost of commercializing it independently.

Cheniere Energy, Inc. engages in liquefied natural gas (LNG) related businesses. It owns and operates LNG terminals, develops, constructs, and operates liquefaction projects near Corpus Christi, Texas, and at the Sabine Pass LNG terminal. The company was founded by Charif Souki in 1983 and is headquartered in Houston, TX.

Cheniere Energy Inc.

Cheniere is drawing attention after strong quarterly results, higher full-year guidance and a dividend increase, fueling bullish momentum and fresh-high chatter. Some traders are taking profits and options positioning is mixed, reflecting caution after the run-up.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons stronger-than-expected third-quarter results are driving the sharp rally, with traders highlighting growth in Dupixent and Eylea HD and the stocks breakout to a new high. The reaction is broadly bullish, though some note that declining legacy Eylea sales and biosimilar competition remain risks.

TRON (TRX) is a cryptocurrency launched in 2018. TRON has a current supply of 95,022,365,191.094644 with 95,022,375,662.737444 in circulation. The last known price of TRON is 0.30232528 USD and is down -8.04 over the last 24 hours. It is currently trading on 1389 active market(s) with $1,465,217,312.79 traded over the last 24 hours. More information can be found at https://trondao.org/.

Tron

TRON is drawing attention for its steady price action, with traders debating whether consolidation and technical support point to further gains or continued stagnation. Some bullish posts also cite the networks stablecoin-transfer activity, while others remain frustrated by the coins slow performance.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

XRP-linked ETF attention centers on reported fund inflows and optimism around regulatory clarity, with some traders viewing institutional demand as supportive while others question whether it has translated into price gains. Discussion also reflects confusion between the XRP token and Bitwises ETF, alongside concern about weakness in the broader crypto market.

Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce. Its platform consists of three core elements: a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The company was founded by Max R. Levchin in 2012 and is headquartered in San Francisco, CA.

Affirm Holdings Inc - Ordinary Shares - Class A

Affirm Holdings Inc

Affirms strong quarterly results and better-than-expected outlook, followed by analyst upgrades, have driven attention. Traders are split after the initial earnings rally reversed sharply: some see profit-taking despite solid growth, while others point to a one-time tax benefit, elevated valuation, and rate and consumer-credit concerns.

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

Blue Owls Q3 results beat expectations, and traders are highlighting growth in assets under management, fee-related earnings, and managements outlook for future fee growth and dividend coverage. Bulls see room for a valuation recovery, while skeptics remain focused on private-credit redemption concerns and put-heavy options activity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for

Cytek Biosciences (CTKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GSK (GSK) Q3 Earnings and Revenues Beat Estimates

Glaxo (GSK) delivered earnings and revenue surprises of +5.00% and +1.24%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week

Ultragenyx agrees to sell its Fayuvi-linked PRV for $203 million, marking its second voucher sale in one week and adding non-dilutive funding for rare-disease programs.

Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?

Ultragenyx's established rare-disease treatments continue to support revenue growth, while two newly approved gene therapies offer additional commercial opportunities.

Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash

RARE enters into an agreement to sell a Rare Pediatric Disease PRV for $210M, adding non-dilutive cash as it advances rare-disease therapies.

Ultragenyx Lands $210M Deal To Sell FDA Priority Review Voucher – Retail Sees ‘Huge’ Buying Opportunity

Equity

The FDA awarded the voucher after approving Genglycos, a glycogen storage disease type Ia treatment, in August.


Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation

RARE's gene therapy for Sanfilippo syndrome wins EMA validation, advancing the treatment toward formal review in Europe.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREPR NewswireNEW YORK, Sept. 24, 2026 NEW YORK, Sept. 24, 2026...

RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results

Ultragenyx shares are trading around $16 after gaining about 9% this week, rebounding from the $12.73 low hit earlier this month. 


Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Bearish Sentiment

<ul class="summary-bullets"><li>A Priority Review Voucher lets its recipient request a faster review of a future drug application or sell the voucher to another company.</li><li>The company said proceeds will support rare-disease programs and its path toward profitability.</li><li>The latest deal marks Ultragenyx’s third PRV sale, with the previous two in 2018.</li></ul>Shares of Ultragenyx Pharmaceutical (RARE) were in focus after the biotech company agreed to sell a Rare Pediatric Disease Priority Review Voucher for $210 million, giving it sizeable non-dilutive capital to support its pipeline.<a href="https://stocktwits.com/symbol/RARE">RARE shares</a> were up 4% at the time of writing, bucking the broader market drawdown and on track for their biggest single-day gain&nbsp;so far this month.<h2 class="st-heading-2">Genglycos Is Ultragenyx’s Third PRV Sale</h2>A Priority Review Voucher (PRV) lets its recipient request a faster review of a future drug application with the U.S. Food and Drug Administration (FDA) or sell the voucher to another company.The FDA awarded the voucher after approving Genglycos, a glycogen storage disease type Ia treatment, in August. Ultragenyx said proceeds from the sale will help fund development of additional rare and ultra-rare disease treatments.“Monetizing this PRV provides significant non-dilutive capital to advance our efforts to bring forward first-ever therapies for rare and ultra-rare diseases, and supports our path to profitability,” said Howard Horn, Ultragenyx’s CFO.The latest deal marks Ultragenyx’s third PRV sale, after the company sold its first two vouchers in 2018 for a combined $210.6 million.<h2 class="st-heading-2">RARE Still Has Four Therapies In Pipeline</h2>Ultragenyx’s pipeline includes four experimental therapies for brain, liver and muscle-related diseases. It also markets four drugs — Crysvita, Dojolvi, Evkeeza and Mepsevii — for a range of rare bone, metabolic, cholesterol and genetic disorders.The latest cash infusion adds to Ultragenyx’s $436 million in cash, cash equivalents and marketable securities as of June 30.<h2 class="st-heading-2">Retail Sees ‘Huge’ Buying Opportunity</h2>Retail sentiment surrounding RARE on Stocktwits remained in the ‘bearish’ zone over the past 24 hours.<img src="https://news.stocktwits-cdn.com/RARE_e434df825a.png" alt="RARE.png">One user saw a “huge buying opportunity” with RARE close to a breakout.<stembedurl>https://stocktwits.com/Idontknownothing55/message/665956550</stembedurl>The stock has been under significant selling pressure this year, falling more than 36%.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/fcel-stock-slumps-amid-cfo-transition-but-retail-calls-ex-xylem-hire-an-encouraging-sign/cZDvghkRBmt">&nbsp;FCEL Stock Slumps Amid CFO Transition — But Retail Calls Ex-Xylem Hire An ‘Encouraging Sign’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ultragenyx Pharmaceutical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

The FDA awarded the voucher after approving Genglycos, a glycogen storage disease type Ia treatment, in August.

Ultragenyx Pharmaceutical Inc

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$16.10
Prev Close	$16.78
Open	$16.64
Dividend Yield	0.00%
50-Day Moving Average	$17.01
Beta	1.06
Avg. Volume	7.13M
PE Ratio	-2.76

52-Week High	$39.89
52-Week Low	$12.73
Market Capitalization	$1.59B
EPS (Annual)	-$5.83
Price to Book	-5.44
Revenue Per Employee	$490,882.57

Feed

News

Sentiment

Earnings

Fundamentals

Info

RARE Fundamentals